The epidemiology of retinopathy of prematurity in the United States

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 48, Issue 7, 2017, Pages 553-562

  Ludwig, Cassie A ^a,b   Chen, Tiffany A ^a   Hernandez Boussard, Tina ^a   Moshfeghi, Andrew A ^c   Moshfeghi, Darius M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Addiction and Pharmacology Research Laboratory   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ARTIFICIAL VENTILATION; ASSISTED VENTILATION; BIRTH INJURY; BIRTH WEIGHT; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CHRONIC RESPIRATORY TRACT DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENCEPHALOMALACIA; FEMALE; FETAL HEMORRHAGE; FETUS HYPOXIA; GENDER; GESTATIONAL AGE; HOSPITAL DISCHARGE; HOSPITAL MORTALITY; HUMAN; INCIDENCE; INFANT; LASER COAGULATION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NECROTIZING ENTEROCOLITIS; NEONATAL HEMORRHAGE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; NEWBORN MORBIDITY; NEWBORN MORTALITY; NONINVASIVE VENTILATION; PARS PLANA VITRECTOMY; PERINATAL INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; SCLERA BUCKLING PROCEDURE; SCLERAL BUCKLE; TREND STUDY; UNITED STATES; CLINICAL TRIAL; HEALTH SURVEY; MULTICENTER STUDY; PROCEDURES; RETINOPATHY OF PREMATURITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; MALE; POPULATION SURVEILLANCE; RETINOPATHY OF PREMATURITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 85025810678     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20170630-06     Document Type: Article

References (37)

1. Steinkuller PG, Du L, Gilbert C, Foster A, Collins ML, Coats DK. Childhood blindness. J AAPOS. 1999;3(1):26-32.
2. Smith LEH. Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res. 2004;14 Suppl A:S140-144.
3. Ng EY, Connolly B P, McNamara JA, Regillo CD, Vander JF, Tas-man W. A comparison of laser photocoagulation with cryo-therapy for threshold retinopathy of prematurity at 10 years: Part 1. Visual function and structural outcome. Ophthalmology. 2002;109(5):928-934.
4. Good WV, Early Treatment for Retinopathy of Prematurity Cooperative Group. Final Results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004;102:233-48; discussion 248-50.
5. Lad EM, Hernandez-Boussard T, Morton JM, Moshfeghi DM. In-cidence of retinopathy of prematurity in the United States: 1997 through 2005. Am J Ophthalmol. 2009;148(3):451-458.
6. Lad EM, Nguyen TC, Morton JM, Moshfeghi DM. Retinopathy of prematurity in the United States. Br J Ophthalmol. 2008;92(3):320-325.
7. Healthcare Cost Utilization Project, Kidś Inpatient Database (KID). Silver Spring, MD: Agency for Healthcare Research and Quality; 1997.
8. Section on Ophthalmology American Academy of Pediatrics; American Academy of Ophthalmology; American Association for Pe-diatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2006;117(2):572-576.
9. Fierson WM, American Academy of Pediatrics Section on Oph-thalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certifed Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131(1):189-195.
10. HCUP Databases. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality; February 2016. www.hcup-us.ahrq.gov/kidoverview.jsp.
11. Gilbert C, Rahi J, Eckstein M, O'Sullivan J, Foster A. Reti-nopathy of prematurity in middle-income countries. Lancet. 1997;350(9070):12-14.
12. Hussain N, Clive J, Bhandari V. Current incidence of retinopathy of prematurity, 1989-1997. Pediatrics. 1999;104(3):e26.
13. Darlow BA, Hutchinson JL, Henderson-Smart DJ, et al. Prenatal risk factors for severe retinopathy of prematurity among very pre-term infants of the Australian and New Zealand Neonatal Net-work. Pediatrics. 2005;115(4):990.
14. Haines L, Fielder AR, Baker H, Wilkinson AR. UK population based study of severe retinopathy of prematurity: Screening, treatment, and outcome. Arch Dis Child Fetal Neonatal Ed. 2005;90(3):F240.
15. Todd DA, Wright A, Smith J, NICUS Group. Severe retinopa-thy of prematurity in infants < 30 weeks' gestation in New South Wales and the Australian Capital Territory from 1992 to 2002. Arch Dis Child Fetal Neonatal Ed. 2007;92(4):F251.
16. Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gyne-col. 2007;196(2):147e1-8.
17. Quinn GE, Gilbert C, Darlow BA, Zin A. Retinopathy of prematurity: An epidemic in the making. Chin Med J (Engl). 2010;123(20):2929-2937.
18. Serenius F, Ewald U, Farooqi A, Holmgren PA, Hakansson S, Se-din G. Short-term outcome after active perinatal management at 23-25 weeks of gestation. A study from two Swedish tertiary care centres. Part 2: Infant survival. Acta Paediatr. 2004;93(8):1081-1089.
19. No authors listed. The natural ocular outcome of premature birth and retinopathy. Status at 1 year. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol. 1994;112(7):903-912.
20. Teoh SL, Boo NY, Ong LC, Nyein MK, Lye MS, Au MK. Duration of oxygen therapy and exchange transfusion as risk factors associated with retinopathy of prematurity in very low birthweight infants. Eye (Lond). 1995;9(Pt 6):733-737.
21. Seiberth V, Linderkamp O. Risk factors in retinopathy of pre-maturity. a multivariate statistical analysis. Ophthalmologica. 2000;214(2):131-135.
22. Chen M, Citil A, McCabe F, et al. Infection, oxygen, and immaturity: interacting risk factors for retinopathy of prematurity. Neona-tology. 2011;99(2):125-132.
23. Slidsborg C, Jensen A, Forman JL, et al. Neonatal Risk Factors for Treatment-Demanding Retinopathy of prematurity: A Danish national study. Ophthalmology. 2016;123(4):796-803.
24. Liu PM, Fang PC, Huang CB, et al. Risk factors of retinopathy of prematurity in premature infants weighing less than 1600 g. Am J Perinatol. 2005;22(2):115-120.
25. Seiberth V, Linderkamp O. Risk factors in retinopathy of pre-maturity. a multivariate statistical analysis. Ophthalmologica. 2000;214(2):131-135.
26. Slidsborg C, Jensen A, Forman JL, et al. Neonatal Risk Factors for Treatment-Demanding Retinopathy of Prematurity: A Danish national study. Ophthalmology. 2016;123(4):796-803.
27. Chiang M F, Arons RR, Flynn JT, Starren JB. Incidence of reti-nopathy of prematurity from 1996 to 2000: Analysis of a com-prehensive New York state patient database. Ophthalmology. 2004;111(7):1317-1325.
28. Yanovitch TL, Siatkowski RM, McCaffree M, Corff KE. Reti-nopathy of prematurity in infants with birth weight > or = 1250 grams: incidence, severity, and screening guideline cost-analysis. J AAPOS. 2006;10(2):128-134.
29. Gunn DJ, Cartwright DW, Gole GA. Prevalence and outcomes of laser treatment of aggressive posterior retinopathy of prematurity. Clin Experiment Ophthalmol. 2014;42(5):459-465.
30. Travassos A, Teixeira S, Ferreira P, et al. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2007;38(3):233-237.
31. Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez-Rojas ML, Salazar-Teran N, Chan RV. Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity. Retina. 2008;28(3 Suppl):S19-25.
32. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevaci-zumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008;28(6):831-838.
33. Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chévez-Barri-os P. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: A morphologic study. Arch Ophthalmol. 2008;126(8):1161-1163.
34. Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prema-turity with intravitreal bevacizumab (Avastin). Retina. 2010;30(4 Suppl):S24-31.
35. Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopa-thy of prematurity: A multicenter study in Taiwan. Ophthalmology. 2011;118(1):176-183.
36. Harder BC, von Baltz S, Jonas JB, Schlichtenbrede FC. Intravitreal bevacizumab for retinopathy of prematurity. J Ocul Pharmacol Ther. 2011;27(6):623-627.
37. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Coop-erative Group. Effcacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603-615.